What happened
A systematic review of 16 randomized trials found that medicines activating both GLP-1 and glucagon receptors reduced body weight and several cardiometabolic risk markers compared with placebo. The trials included 6,611 adults with cardiometabolic disease and lasted at least 12 weeks.
The researchers searched MEDLINE, Embase, and CENTRAL through June 21, 2026. Their primary outcome was the placebo-corrected percentage change in body weight at the end of treatment. Secondary outcomes included waist circumference, glycated hemoglobin, blood pressure measures, total and LDL cholesterol, and triglycerides.
Across the pooled placebo-controlled comparisons, the dual agonists were associated with 7.44 percentage points more weight loss. Expressed as an absolute difference, the estimate was 7.27 kilograms. The uncertainty range ran from 5.43 to 9.44 percentage points for the first estimate and from 5.27 to 9.28 kilograms for the second.
Some included trials used a selective GLP-1 medicine as the comparison instead of placebo. For that analysis, the abstract reported 0.28 mmol/L more triglyceride reduction with the dual medicines. It did not report a pooled finding of greater weight loss than selective GLP-1 therapy.
What it means
The review supports dual GLP-1 and glucagon receptor agonism as an active research approach. Pooling randomized trials gives a broader estimate than relying on one compound or development program, and the placebo comparisons show changes in both weight and metabolic risk markers.
The comparator is important. A medicine can outperform placebo without outperforming an established treatment. The selective GLP-1 comparison in this analysis supported a triglyceride difference, not a general claim that the dual class is better for weight loss.
What it does not mean
A meta-analysis does not turn different medicines, doses, patient groups, and trial lengths into one interchangeable treatment. The pooled estimate is a class-level summary, not the expected result for every compound or every patient.
Changes in cholesterol, blood pressure, glycated hemoglobin, or triglycerides are risk-factor findings. They do not by themselves prove fewer heart attacks, strokes, or deaths. The authors called for large outcome studies to test those questions.
The review also does not establish regulatory approval or clinical availability for every drug included. Development status and approved uses must be checked compound by compound.
Educational information only. This brief is not medical advice. Do not start, stop, or change treatment based on it.
How this brief was reported
Obesity Treatment News is a BariatricPal publication. We review linked source material, explain what changed, and state what the evidence does not establish.
Editorial standards, corrections, and commerce disclosure · About BariatricPal · About the brief author · Contact BariatricPal